Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2016 - 2025)

Ironwood Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 83419000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 3797.65% year-over-year to 83419000.0; the TTM value through Dec 2025 reached 56091000.0, down 6041.84%, while the annual FY2025 figure was 115147000.0, 12984.89% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 83419000.0 at Ironwood Pharmaceuticals, down from 40040000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 391303000.0 in Q2 2021 and bottomed at 1089522000.0 in Q2 2023.
  • The 5-year median for Income from Continuing Operations is 30322500.0 (2022), against an average of 27198850.0.
  • The largest YoY upside for Income from Continuing Operations was 2839.53% in 2025 against a maximum downside of 3797.65% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 41383000.0 in 2021, then surged by 177.04% to 114647000.0 in 2022, then plummeted by 299.1% to 228262000.0 in 2023, then surged by 100.99% to 2256000.0 in 2024, then plummeted by 3797.65% to 83419000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Income from Continuing Operations are 83419000.0 (Q4 2025), 40040000.0 (Q3 2025), and 23560000.0 (Q2 2025).